A
Alcista
Alcista · 25%JAZZ
$101.77
Precio del escenario
$213.760
+5.472 (+2.56%)Al cierre
Loading chart…
- Máximo
- 215.545
- Apertura
- 209.890
- Precio medio ponderado por volumen
- 212.76
- Volumen
- 663.27K
- Capitalización
- 6.75B
- Mínimo
- 208.980
- Importe
- 141.12M
- EV/EBITDA, TTM
- 7.91
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Análisis de IA of Jazz Pharmaceuticals PLC (JAZZ)
MantenerJazz Pharmaceuticals is currently a hold. The stock's current price is $210.23, with a forward P/E ratio of 10.89, suggesting it may be undervalued compared to its earnings potential. However, the RSI is at 24.01, indicating that the stock is oversold, and the recent 5-day change is -3.75%, reflecting downward momentum. The main risk is the recent volatility in earnings, with a net income of -$71.8 million in Q2 2025, which raises concerns about profitability moving forward.
Recomendaciones de analistas (21)
+2.41% de potencial alcista
Comprar
16 Comprar
5 Mantener
0 Vender
Actual: 213.76
Mínimo
188.00
Promedio
218.92
Máximo
263.00
BofA
Comprar
$313
2026-10-09
BofA
2026-10-09
Precio objetivo
$313
Comprar
RBC Capital
Superar al mercado
$296
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$296
Superar al mercado
Truist
Comprar
$286
2026-10-07
Truist
2026-10-07
Precio objetivo
$286
Comprar
Citi
Comprar
$325
2026-09-30
Citi
2026-09-30
Precio objetivo
$325
Comprar
Goldman Sachs
Comprar
$337
2026-09-24
Goldman Sachs
2026-09-24
Precio objetivo
$337
Comprar
Métricas de valoración
El PER previsto actual de Jazz Pharmaceuticals PLC (JAZZ) es 10.89, frente a su media de 5 años de 7.87.
Escenarios de precio de Alphio AI para JAZZ
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con JAZZ en cartera
Cronología de eventos
Noticias
9.510-19PRnewswireJazz Pharmaceuticals to Report Q3 2026 Financial Results
6.510-09CNBCInvestor Perspectives on Multiple Companies Analyzed
4.009-30CNBCAnalyst Ratings Update: Apple, Tesla, and More
6.009-24CNBCLatest Wall Street Rating Updates
8.509-18FoolJazz Pharmaceuticals Acquires Actio for $820 Million, Targeting Childhood Epilepsy Treatment
Preguntas frecuentes sobre JAZZ, respondidas por Alphio AI
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Jazz Pharmaceuticals is currently a hold. The stock's current price is $210.23, with a forward P/E ratio of 10.89, suggesting it may be undervalued compared to its earnings potential. However, the RSI is at 24.01, indicating that the stock is oversold, and the recent 5-day change is -3.75%, reflecting downward momentum. The main risk is the recent volatility in earnings, with a net income of -$71.8 million in Q2 2025, which raises concerns about profitability moving forward.
21 analysts cover JAZZ: 16 rate it Buy, 5 Hold and 0 Sell. The average price target is 218.92.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.